Cystic fibrosis (CF) is the most common inherited rare disease in North America and Europe, with more than 27,000 cases in the US and more than 35,000 cases in the European Union (EU) (Cystic Fibrosis Foundation Patient Registry, 2011; Farrell, 2008). CF causes abnormally thick, sticky mucus to accumulate in the respiratory, digestive, and reproductive systems. It is one of the most common chronic lung diseases and is widespread throughout the world. The specific defective gene that cases CF is the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Key differences in the CF epidemiology between countries are influenced by genotype mutations, national screenings, and surveillance systems through national registries. GlobalData forecasts that the US and UK will have the most prevalent cases of CF in 2022. In 2022, the combined prevalent CF cases in the 5EU countries (France, Germany, Italy, Spain, and the UK) will be slightly larger than the number of prevalent CF cases in the US.
The UK and France will have the greatest prevalence proportions (0.0157% and 0.0097%, respectively) and the largest 10-year growth (33.2% and 38.1%, respectively), implying that this may be the result of a higher prevalence of CF gene mutations in these populations. The high number of prevalent cases of CF in the US is due to all 50 states screening for CF in newborns. National CF screenings are imperative in detecting and capturing the true prevalence of the disease in a given country.
- The cystic fibrosis EpiCast Report and EpiCast Model provides an overview of the risk factors and comorbidities associated with cystic fibrosis, as well as global trends in prevalence in the six major markets (the US, France, Germany, Italy, Spain, and the UK). It also includes a 10-year epidemiological forecast of prevalent cases of cystic fibrosis segmented by sex, age (segmented by five-year age groups, beginning at age 0 years and ending at =35 years), and mutation type (F508del, G551D, G54X, W1282X, 621+1G>1, R553X, and 3950delT).
Reasons To Buy
- Develop business strategies by understanding the trends shaping and driving the global cystic fibrosis market.
- Quantify patient populations in the global cystic fibrosis market to improve product development, pricing, and launch plans.
- Organize sales and marketing efforts by identifying sex and age groups that present the best opportunities for cystic fibrosis therapeutics in each of the markets covered.
Table of Contents
1 Executive Summary 1
2 Table of Contents 3
2.1 List of Tables 5
2.2 List of Figures 5
3 Introduction 6
3.1 Catalyst 6
3.2 Upcoming Reports 6
4 Epidemiology 7
4.1 Risk Factors and Comorbidities 7
4.1.1 The occurrence of cystic fibrosis is approximately one in 2,500 Caucasians 7
4.1.2 Increased cystic fibrosis life expectancy increases comorbidities of CF-related diabetes and bone disease 8
4.2 Global Trends 8
4.2.1 United States 8
4.2.2 France 9
4.2.3 Germany 9
4.2.4 Italy 10
4.2.5 Spain 10
4.2.6 United Kingdom 10
4.3 Forecast Methodology 11
4.3.1 Sources Used 11
4.3.2 Forecast Assumptions and Methods 13
4.3.3 Sources Not Used 15
4.4 Epidemiology Forecast 15
4.4.1 Total Prevalent Cases of Cystic Fibrosis 15
4.4.2 Total Prevalent Cases of Cystic Fibrosis Segmented by Age 17
4.4.3 Total Prevalent Cases of Cystic Fibrosis Segmented by Sex 18
4.4.4 Total Prevalent Cases of Cystic Fibrosis by Mutation Type 19
4.5 Discussion 21
4.5.1 Conclusion on Epidemiology Trends 21
4.5.2 Limitations of the Analysis 21
4.5.3 Strengths of the Analysis 21
5 Appendix 22
5.1 Bibliography 22
5.2 About the Authors 26
5.2.1 Epidemiologists 26
5.2.2 Reviewers 26
5.2.3 Global Director of Epidemiology and Clinical Trials Analysis 27
5.2.4 Global Head of Healthcare 27
5.3 About GlobalData 29
5.4 About EpiCast 29
5.5 Contact Us 29
5.6 Disclaimer 30
List of Table
List Of Tables
Table 1: Six Major Markets, Sources of Cystic Fibrosis Prevalence Data 11
Table 2: Six Major Markets, Sources of Cystic Fibrosis-Causing Mutation Data 12
Table 3: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0–35 Years, Males and Females, Selected Years, 2012–2022 16
Table 4: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0–35 Years, By Sex, 2012 , N (%) 19
Table 5: Six Major Markets, Cystic Fibrosis Prevalent Cases Segmented by Mutation Type, Ages 0–35 Years, Males and Females, 2012 19
List of Chart
List Of Figures
Figure 1: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0–35 Years , Males and Females, Selected Years, 2012–2022 1
Figure 2: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0–35 Years, Males and Females, Selected Years, 2012–2022 16
Figure 3: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, By Age, Males and Females, 2012 18
Figure 4: Six Major Markets, Cystic Fibrosis Prevalent Cases Segmented by Mutation Type, Ages 0–35 Years, Males and Females, 2012 20
Make an enquiry before buying this Report
Please fill the enquiry form below.